SYS-CON MEDIA Authors: Kevin Benedict, Gilad Parann-Nissany, Michael Bushong, Eric Brown

News Feed Item

Ken Keller Named President, US Commercial, Daiichi Sankyo, Inc.

PARSIPPANY, N.J., April 18, 2014 /PRNewswire/ -- Daiichi Sankyo, Inc. announced today that Ken Keller will join the company as President of its Commercial operations in the United States starting May 1, 2014.  In his role, Mr. Keller will be responsible for leading marketing, sales, medical affairs and supply chain operations for Daiichi Sankyo in the U.S.

"We are very pleased to welcome Ken Keller into the Daiichi Sankyo family," said Joji Nakayama, President and CEO of Daiichi Sankyo Co., Ltd., the parent company of the Daiichi Sankyo Group.  "Ken brings with him more than 25 years of pharmaceutical experience, with career highlights including building a $3 billion business unit as well as leading commercialization for four of the world's top selling biologic medicines.  His broad experience and proven success will be a tremendous asset to Daiichi Sankyo." 

Most recently, Mr. Keller was Executive Vice President and Chief Operating Officer at Spectrum Pharmaceuticals, where he was responsible for global commercial, medical, research and development, and manufacturing.  Also responsible for business development at Spectrum, he was integral to the successful acquisition and integration of Talon Therapeutics into the company.

Prior to Spectrum, Mr. Keller spent 21 years at Amgen rising through the organization as a respected leader in sales and marketing, general management and joint ventures.  He brings with him deep experience in several therapeutic areas aligned with Daiichi Sankyo's focus, including oncology and primary care medicines.  His most recent appointments at Amgen were as Vice President and General Manager for two of the company's highly successful business units (bone health and inflammation), as well as Managing Director at Amgen Limited in the United Kingdom and Ireland. 

With the appointment of Mr. Keller as the head of commercial operations at Daiichi Sankyo, Inc., Dr. Glenn Gormley will assume the role of Executive Chairman and President, Daiichi Sankyo, Inc., and will retain his roles as President, Daiichi Sankyo Pharma Development and as the Global Head of R&D for Daiichi Sankyo Co., Ltd.  Greg Barrett, who served as interim president for Commercial operations for the past seven months, will remain Vice President of Marketing and Managed Markets at Daiichi Sankyo, Inc.

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group.  For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.

SOURCE Daiichi Sankyo, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.